9001cc½ðɳ

English

9001cc½ðɳÉúÎïѪ˨ËÄÏî | ΪDICÔçÆÚÕï¶ÏÌṩÓÐÁ¦Ö§³Ö

°ä²¼ÓÚ£º2024-12-20

ÎÄÕÂÆðÔ´£º[ÖÐÎÄ]9001cc½ðɳÉúÎï




01

DIC¸ÅÊö


ÃÖÉ¢ÐÔѪ¹ÜÄÚÄýѪ£¨disseminated intravascular coagulation£¬£¬£¬£¬£¬DIC£©ÊÇÔںܶ༲²¡»ù´¡ÉÏ£¬£¬£¬£¬£¬Ö²¡³É·ÖΣÏÕ΢Ѫ¹Üϵͳ£¬£¬£¬£¬£¬µ¼ÖÂÄýѪ»î»¯£¬£¬£¬£¬£¬È«Éí΢Ѫ¹ÜѪ˨Ðγɡ¢ÄýѪÒò×Ó´óÁ¿¿÷Ë𲢼̷¢ÏËÈÜ¿º½ø£¬£¬£¬£¬£¬ÒýÆðÒÔ³öѪ¼°Î¢Ñ­»·Ë¥½ßÎªÌØµãµÄÁÙ´²×ÛºÏÕ÷¡£¡£¡£¡£¡£¡£¡£


DIC²»ÊÇÒ»¸ö¶ÀÁ¢µÄ¼²²¡£¬£¬£¬£¬£¬¶øÊǶà¶à¼²²¡¸´ÔÓ²¡Àí¹ý³ÌÖеÄÖÐÑë»·½Ú£¬£¬£¬£¬£¬Æä»ù´¡¼²²¡»òÓÕÒòÔ̺¬£ºÑϳÁϰȾ£¨Å§¶¾Ö¢µÈ£©¡¢¶ñÐÔÖ×Áö¡¢²¡Àí²ú¿Æ¡¢±í¿ÆÊÖÊõ¼°±íÉËÖж¾ºÍÃâÒßΣÏյȣ¬£¬£¬£¬£¬ÆäÖÐϰȾÊÇ×î³£¼ûµÄÔ­Òò¡£¡£¡£¡£¡£¡£¡£


DIC¼²²¡Ìص㣺Æð²¡ÒþÄ䣬£¬£¬£¬£¬ÔçÆÚ¿ÉÎÞÏÔÖøÌØµã£¬£¬£¬£¬£¬ÓµÓнøÕ¹¿ì¡¢Ô¤ºó²î¡¢éæÃüÂʸߵµ¡£¡£¡£¡£¡£¡£¡£


DICʹ»¼Õ߯÷¹ÙË¥½ßºÍéæÃüµÄΣÏÕÐÔÏÔÖøÔö³¤£¬£¬£¬£¬£¬ÔÚ·ÖÆç±¨Â·ÖУ¬£¬£¬£¬£¬DIC»¼Õß²¡ËÀÂʸߴï31%~86%£¬£¬£¬£¬£¬Òò¶øÓÐѧÕß°ÑDICг³ÆÎª¡°Death Is Coming¡±¡£¡£¡£¡£¡£¡£¡£ÓÉÓÚDIC»ù´¡¼²²¡ºÍÁÙ´²²û·¢¶àÑù»¯¡¢·ÔìÚ¸´ÔÓ£¬£¬£¬£¬£¬Ê¹ÆäÈÝÒ×ÓëÆäËûÒýÆð³öÄýѪÒì³£¼²²¡Ïà»ìºÏ£¬£¬£¬£¬£¬¼«Ò×±»ºöÊÓ£¬£¬£¬£¬£¬ÑϳÁÓ°Ï컼ÕßÔ¤ºó£¬£¬£¬£¬£¬Òò¶øDICµÄÔçÆÚÕï¶ÏÊÇDICÕïÖεĹؼü¡£¡£¡£¡£¡£¡£¡£





9001cc½ðɳÉúÎïѪ˨ËÄÏîÒÑ»ñµÃ×¢²áÖ¤£¬£¬£¬£¬£¬ÔÚDICÔçÆÚÕï¶ÏÄܹ»ÌṩÓÐÁ¦Ö§³Ö£¡



02

DICÕï¶Ï³ß¶ÈµÄ½ü¿ö


DICµÄ·¢³¯ÆøÔ츴ÔÓ£¬£¬£¬£¬£¬Ö²¡³É·Ö·ÖÆç£¬£¬£¬£¬£¬Æä¶ÔÓ¦µÄ²¡ÀíÉúÀí»úÔì¼°ÁÙ´²ÌصãÒ²´æÔںܴó²î¾à£¬£¬£¬£¬£¬DICµÄÕï¶ÏÊÇĿǰÁÙ´²´æÔÚµÄÒ»¸öÄÑÌâ¡£¡£¡£¡£¡£¡£¡£



ĿǰָÄÏÍÆ¼öʹÓùú¼ÊѪ˨ÓëֹѪѧ»á³ß¶È£¨ISTH-DIC£©¡¢ÖйúDICÕï¶Ï»ý·Öϵͳ£¨CDSS-DIC£©ÆÀ·ÖϵͳÕï¶ÏDIC¡£¡£¡£¡£¡£¡£¡£´Ë±í£¬£¬£¬£¬£¬2019ÄêISTH°ä²¼ÁËŧ¶¾Ö¢ÐÔÄýѪ²¡(sepsis-induced coagulopathy£¬£¬£¬£¬£¬SIC)Õï¶Ï³ß¶È£¬£¬£¬£¬£¬¹ÌÈ»ÏÖ´æºÃ¶àDICÕï¶Ï³ß¶È£¬£¬£¬£¬£¬µ«ÊǸ÷×Ô´æÔڿ϶¨µÄ¾ÖÏÞÐÔ£¬£¬£¬£¬£¬¶ÔDICÔçÆÚÕï¶Ï¼°DICÔ¤ºóÅжϻîÂç¶ÈºÍÌØÒì¶È¾ùÓдýÌá¸ß£¬£¬£¬£¬£¬ÓÈÆäÊǶÔéæÃüµÄÅжÏÒÔ¼°pre-DICµÄÕï¶Ï£¬£¬£¬£¬£¬Ä¿Ç°ÈÔ²»×ãDICÕï¶ÏµÄ½ð³ß¶È¡£¡£¡£¡£¡£¡£¡£Òò¶øÁÙ´²ÉϱØÒªÒÀ¸½ÐµÄÄýѪ·Ö×Ó±êÖ¾Îï³ÉÁ¢Ð§Á¦¸ü¸ßµÄDIC¾«×¼Õï¶Ïϵͳ¡£¡£¡£¡£¡£¡£¡£½üÄê×êÑнøÕ¹¿ì¡¢ÁÙ´²Áìµ¼Òâ˼ǿµÄÐÂÐÍÄýѪ·Ö×Ó±êÖ¾ÎïÔ̺¬ÄýѪø-¿¹ÄýѪø¸´ºÏÎï(thrombin-antithrombin compex£¬£¬£¬£¬£¬TAT)¡¢ÏËÈÜø-¿¹ÏËÈÜø¸´ºÏÎï(plasmin antiplasmincomplex£¬£¬£¬£¬£¬PIC)¡¢×éÖ¯ÐÍÏËÈÜøԭ¼¤»îÎï-ÏËÈÜøԭ¼¤»îÒÖÔìÎï-1¸´ºÏÎï(tissue plasminogen activator-plasminogen activator inhibitor-l complex£¬£¬£¬£¬£¬t-PAIC)¼°ÑªË¨µ÷½Úµ°°×(thrombomodulin£¬£¬£¬£¬£¬TM)¡£¡£¡£¡£¡£¡£¡£



03
 

ÐÂѪ˨ËÄÏîÖúÁ¦DICÔçÕïÔçÖÎ


2017Ä꣬£¬£¬£¬£¬¡¶ÖлªÑªÒºÑ§ÔÓÖ¾¡·°ä·¢µÄ¡¼ûÖÂþÐÔѪ¹ÜÄÚÄýѪÕï¶ÏÖйúר¼Ò¹²Ê¶¡·TAT¿ÉÓÃÓÚDICÔçÆÚÕï¶Ï¡£¡£¡£¡£¡£¡£¡£Í¬Ä꣬£¬£¬£¬£¬ÈÕ±¾ÑªË¨ÓëֹѪѧ»á£¨JSTH£©DICÕï¶Ï³ß¶ÈÖÐÒýÈëÁËTAT¼ì²â¡£¡£¡£¡£¡£¡£¡£2020Ä꣬£¬£¬£¬£¬¡¶Öлª¼¹ØïҽѧÔÓÖ¾¡·°ä·¢µÄ¡¶¼±ÐÔ³öѪÐÔÄýѪְÄÜ×è°­ÕïÖÎר¼Ò¹²Ê¶¡·ÖÐÖ¸³ö£¬£¬£¬£¬£¬ÑªË¨·Ö×Ó±êÖ¾Î£¬£¬£¬£¬TAT¿ÉÔçÆÚÔ¤²âѪ˨Ðγɺ͸´·¢·çÏÕ£¬£¬£¬£¬£¬ÔçÆÚÔ¤²âDIC·çÏÕ£»£»£»£»£»PIC¿ÉÓÃÓÚDIC·ÖÐÍ¡¢ÈÜ˨ҽÖΣ»£»£»£»£»tPAIC¶ÔDIC¡¢¶¯¾²ÂöѪ˨¾ùÓÐÌáÐÑ×÷Ó㻣»£»£»£»TM¿ÉÌáÐÑѪ¹ÜÄÚÆ¤Î£ÏտɼûÓÚŧ¶¾Ö¢¡¢ÉöÖ°ÄÜÊÜËðºÍ¼±ÐÔ·ÎΣÏյȡ£¡£¡£¡£¡£¡£¡£¶ÔÓÚÁÙ´²Çé¿ö¸´ÔӵϼÕߣ¬£¬£¬£¬£¬ÍƼöʹÓÃTAT¡¢PIC¡¢tPAIC¡¢TM×÷ÔçÆÚÆÀ¹À¡£¡£¡£¡£¡£¡£¡£


1

TAT  ÄýѪø-¿¹ÄýѪø¸´ºÏÎï

ÌåÄÚÄýѪøÐγɺ󣬣¬£¬£¬£¬²¿ÃÅѸËÙÓ뿹ÄýѪø(antithrombin£¬£¬£¬£¬£¬AT)½áºÏÐγÉTAT£¬£¬£¬£¬£¬¸ÃÖ¸±êÊÇ·´Ó³ÄýѪøÌìÉúµÄ·Ö×Ó±êÖ¾Î£¬£¬£¬£¬¿É»îÂçµØ·´Ó³ÄýѪϵͳµÄ¼¤»îˮƽ£¬£¬£¬£¬£¬Ö±½Ó·´Ó³ÄýѪϵͳÆô¶¯¡£¡£¡£¡£¡£¡£¡£ÄýѪøÔÚѪҺÖаëË¥ÆÚ½öÊýÃ룬£¬£¬£¬£¬Ö±½Ó²â¶¨ÄÑÌâ¡£¡£¡£¡£¡£¡£¡£TATµÄѪ½¬°ëË¥ÆÚΪ3~15 min£¬£¬£¬£¬£¬Äܹ»Ö±½Ó²â¶¨£¬£¬£¬£¬£¬TATѪ½¬Õý³£ÖµÎª<4 ng/mL£¬£¬£¬£¬£¬TAT>4 ng/mL£¬£¬£¬£¬£¬ÌáÐÑÄýѪøºÏ³ÉÔö¶à¡£¡£¡£¡£¡£¡£¡£TATÉý¸ß¿ÉÔçÆÚÔ¤²âѪ˨Ðγɺ͸´·¢·çÏÕ¡¢ÔçÆÚÔ¤²âDIC·çÏÕ¡£¡£¡£¡£¡£¡£¡£

2

PIC  ÏËÈÜø-¿¹ÏËÈÜø¸´ºÏÎï

PICÊÇÏËÈÜøÓëÒÖÔìÒò×Ó¦Á2¿¹ÏËÈÜøÒÔ1:1½áºÏÐγɵĸ´ºÏÎ£¬£¬£¬£¬ÊÇÖ±½Ó·´Ó³ÏËÈÜϵͳ¼¤»îˮƽµÄÉúÎï±êÖ¾Îï¡£¡£¡£¡£¡£¡£¡£PICѪ½¬°ëË¥ÆÚÔ¼6h£¬£¬£¬£¬£¬¿ÉÖ±½Ó²â¶¨£¬£¬£¬£¬£¬Ñª½¬Õý³£ÖµÎª<0.8¦Ìg/mL£¬£¬£¬£¬£¬PIC>0.8 ¦Ìg/mL³£ÌáÐÑÏËÈÜϵͳ¼¤»î¡£¡£¡£¡£¡£¡£¡£ÏËÈܼ¤»îˮƽÒòDIC»ù´¡¼²²¡·ÖÆç¶øÓÐËù²î¾à£¬£¬£¬£¬£¬ÇÒÓëDIC·ÖÐÍÇ×êÇÓйØ£¬£¬£¬£¬£¬¿ÉÓÃÓÚÔçÆÚÔ¤²â¸ßÄý״̬£¬£¬£¬£¬£¬Ò²¿ÉÓÃÓÚÈÜ˨ҽÖμà²â¡£¡£¡£¡£¡£¡£¡£

3

t-PAIC  ×éÖ¯ÐÍÏËÈÜøԭ¼¤»îÎï-ÏËÈÜøԭ¼¤»îÒÖÔìÎï-1¸´ºÏÎï

Ѫ¹ÜÄÚÆ¤Ï¸°ûΣÏÕʱ£¬£¬£¬£¬£¬×éÖ¯ÐÍÏËÈÜøԭ¼¤»îÎï¼°ÏËÈÜøԭ¼¤»îÒÖÔìÎï-1ͬʱ¿ªÊ͵½ÑªÒºÖУ¬£¬£¬£¬£¬1:1½áºÏÐγÉtPAIC£¬£¬£¬£¬£¬tPAIC¿ÉÄÜ·´Ó³ÄÚÆ¤Ï¸°ûµÄΣÏÕ£¬£¬£¬£¬£¬ÊÇÏËÈÜϵͳ¼¤»îµÄ·Ö×Ó±êÖ¾Î£¬£¬£¬£¬ÄÐÐÔѪ½¬Õý³£Öµ<17.0 ng/mL£¬£¬£¬£¬£¬Å®ÐÔ<10.5 ng/mL¡£¡£¡£¡£¡£¡£¡£tPAIC ¶ÔDIC¡¢¶¯¾²ÂöѪ˨¾ùÓÐÌáÐÑ×÷Ó㬣¬£¬£¬£¬ÊǾ²ÂöѪ˨˨ÈûÖ¢(veinthromboembolism,VTE)¼°ÐĹ£µÄ·çÏÕÖ¸±ê£¬£¬£¬£¬£¬´Ë±í¸ÃÖ¸±ê¶ÔDICÕï¶ÏÓµÓгÁÒª¼ÛÖµ£¬£¬£¬£¬£¬Ñª½¬Ë®Æ½Éý¸ßÌáÐÑDIC¿ÉÄÜѪ¹ÜÄÚÆ¤Ï¸°ûΣÏÕ¡¢ÑªË¨Ðγɡ£¡£¡£¡£¡£¡£¡£

4

TM  Ѫ˨µ÷½Úµ°°×

TMΪÄÚÆ¤Ï¸°û±í±íµÄÄýѪøÊÜÌ壬£¬£¬£¬£¬ÒÖÔìÄýѪøµÄ»îÐÔ£¬£¬£¬£¬£¬¼ÓÇ¿µ°°×C»î»¯»úÄÜ£¬£¬£¬£¬£¬Ñª½¬TMÕý³£ÖµÎª3.8~13.3 TU/mL¡£¡£¡£¡£¡£¡£¡£µ±ÄÚÆ¤Ï¸°ûÊÜËð»òÖ°ÄÜ×谭ʱ£¬£¬£¬£¬£¬TM±í°×½µµÍ£¬£¬£¬£¬£¬²¿ÃÅTM±»µ°°×øˮ½âÖÁѪ½¬ÖÓ×£¡£¡£¡£¡£¡£¡£Òò¶ø£¬£¬£¬£¬£¬TMÊÇÄÚÆ¤Ï¸°ûÊÜËðµÄ±êÖ¾Îï¡£¡£¡£¡£¡£¡£¡£TMÉý¸ßÌáÐÑѪ¹ÜÄÚÆ¤Î£ÏÕ£¬£¬£¬£¬£¬¿É¼ûÓÚŧ¶¾Ö¢¡¢ÉöÖ°ÄÜÊÜËð¡¢¼±ÐÔ·ÎΣÏյȡ£¡£¡£¡£¡£¡£¡£


ÐÂѪ˨ËÄÏî½áºÏ¼ì²â¶ÔÕï¶ÏDICµÄ¼ÛÖµ¸ü¸ß


Ò»Ïî¶àÖÐÐÄǰհÐÔ¹Û²ì×êÑÐÅú×¢TAT¡¢PIC¡¢tPAICºÍsTMÔÚ·ÖÆç»ù´¡¼²²¡µÄDIC»¼ÕßÖвû·¢³öÓÅÁ¼µÄÕï¶Ï»úÄܺÍÔ¤ºó¼ÛÖµ£¬£¬£¬£¬£¬TAT¡¢tPAICºÍsTMÔÚpre-DICµÄÕï¶ÏÓµÓп϶¨µÄÒâ˼¡£¡£¡£¡£¡£¡£¡£´Ë±í£¬£¬£¬£¬£¬ÐÂѪ˨ËÄÏî½áºÏ¼ì²â¿ÉÔö³¤AUC¡¢»îÂç¶ÈºÍÓÅÊÆ±È£¬£¬£¬£¬£¬ÓµÓиü¸ßµÄ¼ì²âЧÁ¦£¬£¬£¬£¬£¬ÓÐÖúÓÚʵʱ¹ýÎÊ¡£¡£¡£¡£¡£¡£¡£



×ÛÉÏËùÊö£¬£¬£¬£¬£¬DIC»ù´¡¼²²¡¶àÑù£¬£¬£¬£¬£¬ÁÙ´²·ÔìÚ¸´ÔÓ£¬£¬£¬£¬£¬ÓëÆäËûѪ˨ÐÔ¼²²¡µÄÕç±ðÕï¶Ï½ÏÄÑÌ⣬£¬£¬£¬£¬¼«Ò×±»ºöÊÓ£¬£¬£¬£¬£¬Ê¹ÓÃͨÀýÄýѪָ±êÕï¶ÏDICʱ£¬£¬£¬£¬£¬DIC»¼ÕßÍùÍùÒѾ­½øÈëÖÐÍíÆÚ£¬£¬£¬£¬£¬´Ëʱ»¼ÕßµÄÔ¤ºóͨ³£½Ï²î£¬£¬£¬£¬£¬ÄýѪ¡¢ÏËÈÜϵͳ´íÂÒ£¬£¬£¬£¬£¬ÄÑÒÔ¸´Ô­Õý³£Ë®Æ½£¬£¬£¬£¬£¬ÒײúÉú¶àÆ÷¹ÙÖ°ÄÜ×è°­×ÛºÏÕ÷£¨MODS£©£¬£¬£¬£¬£¬²¡ËÀÂʼ«¸ß¡£¡£¡£¡£¡£¡£¡£ÐÂѪ˨ËÄÏîTM¡¢TAT¡¢PIC¡¢t-PAICÔÚDICÔçÆÚÕï¶ÏÖÐÓµÓÐÁìµ¼Òâ˼£¬£¬£¬£¬£¬²¢ÇÒ±ÈͨÀýÄýѪָ±ê¸üÔçÌáÐÑÄýѪÓëÏËÈÜϵͳÒì³££¬£¬£¬£¬£¬Åú×¢Æä¶ÔÔçÆÚDICÓµÓÐÓÅÁ¼µÄÕï¶Ï¼ÛÖµ¡£¡£¡£¡£¡£¡£¡£Í¨¹ýÐÂѪ˨ËÄÏî¼ì²â£¬£¬£¬£¬£¬¿ÉÖúÁ¦ÁÙ´²¾«×¼ÅжÏDICµÄʱÆÚ£¬£¬£¬£¬£¬ÌáÐÑÁÙ´²¼°Ôç½øÐйýÎʲ¢µ÷ÕûÒ½Öι滮¡£¡£¡£¡£¡£¡£¡£




9001cc½ðɳѪ˨ËÄÏî²úÆ·½éÉÜ


? ²½Öèѧ£º´Å΢Á£»£»£»£»£»¯Ñ§·¢¹â·¨

? Ñù±¾ÀàÐÍ£ºèÛéÚËáÄÆÑª½¬

? Ð£×¼ÖʿأºËæºÐÔùËÍ

? ºÏÓûúÐÍ£ºÈ«ÐÂÈý¿îÈ«×Ô¶¯»¯Ñ§·¢¹âÒÇÆ÷¡£¡£¡£¡£¡£¡£¡£ÓµÓÐÕ¼µØÓ×£¬£¬£¬£¬£¬²âÊÔËٶȿ죬£¬£¬£¬£¬½Ã½ÝÐԸߵÅ×ÅÊÆ£¬£¬£¬£¬£¬Äܹ»Âú×ã¶àÖÖÖն˿ͻ§ÐèÒª¡£¡£¡£¡£¡£¡£¡£



²Î¿¼Îļþ

[1] ÖлªÒ½Ñ§»áѪҺѧ·Ö»áѪ˨ÓëֹѪѧ×飮ÃÖÉ¢ÐÔѪ¹ÜÄÚÄýѪÕï¶ÏÖйúר¼Ò¹²Ê¶(2017Äê°æ)[J]. ÖлªÑªÒºÑ§ÔÓÖ¾, 2017, 38(5):361-363.

[2] ÍõÁ¦¾ü£¬£¬£¬£¬£¬²ñÑÞ·Ò. ŧ¶¾Ö¢²¢·¢ÃÖÉ¢ÐÔѪ¹ÜÄÚÄýѪÕïÖμ¹Øïר¼Ò¹²Ê¶[J].ʵÓüìÑéҽʦÔÓÖ¾, 2017, 03(v.9):7-10.DOI:CNKI:SUN:CJCP.0.2017-03-003.

[3] ºú×ÏÞ±,ÂíÏþ´º.ÃÖÉ¢ÐÔѪ¹ÜÄÚÄýѪÕï¶Ï³ß¶È£ºÎÊÌâÓë½øÕ¹[J].ÖйúʵÓÃÄÚ¿ÆÔÓÖ¾,2021,41(06):457-461.DOI:10.19538/j.nk2021060101.

[4] Ëξ°´º,ÕÅΰ,ÕÅÀÚ,µÈ.³ÁÖ¢»¼ÕßÄýѪְÄÜ×è°­³ß¶È»¯ÆÀ¹ÀÖйúר¼Ò¹²Ê¶[J].½â·Å¾üҽѧÔÓÖ¾,2022,47(02):107-117.

[5] ÉÛÃã,ѦÃ÷Ã÷,Íõ˼¼Ñ,µÈ.¼±ÐÔ³öѪÐÔÄýѪְÄÜ×è°­ÕïÖÎר¼Ò¹²Ê¶[J].Öлª¼¹ØïҽѧÔÓ,2020,29(6):780-787.

[6] Wada H, Takahashi H, Uchiyama T, et al. The approval of revised diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis[J]. Thrombosis Journal, 2017,15(1).

[7] Mei H, Jiang Y, Luo L, et al. Evaluation the combined diagnostic value of TAT, PIC, tPAIC, and sTM in disseminated intravascular coagulation: A multi-center prospective observational study. Thromb Res. 2019;173:20-26.


END

ÎÄÕÂÆðÔ´£º9001cc½ðɳÉúÎï

Ôð±à£ºEcho

У¶Ô£ºPretty¡¢Miss Jia


 
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿